EVALUATING THE ROLE OF MICROBIAL DYSBIOSIS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): POTENTIAL FOR TARGETED THERAPIES

Abstract

The modulation of immune checkpoints has emerged as a compelling therapeutic strategy for managing autoimmune disorders, offering a targeted alternative to conventional immunosuppressive therapies. This study explores the evolving role of checkpoint inhibitors such as CTLA-4, PD-1, PD-L1, and novel targets like OX40 and LAG-3 in restoring immune tolerance while minimizing systemic side effects. Through a comprehensive secondary analysis of recent clinical trials and preclinical investigations, the research identifies key therapeutic outcomes associated with checkpoint inhibition, including reductions in disease flare frequency, improved biomarker profiles, and enhanced remission rates in conditions like rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. The results presented in 4 tables demonstrate successfully running trials, the need for biomarker-based patient subtyping, and the effectiveness of unique strategies like CAR-T cell therapy and engineered regulatory T cells to eliminate autoreactive immune cells selectively. Furthermore, eleven figures that are presented additionally emphasize the effects of these therapies on outcomes, providing information about immunomodulation tendencies in different models of autoimmune diseases. As the results of the study are indicating, it also stresses the need for the application of the concept of the personalized medicine in management of immune checkpoint intervention, taking into account the specific immunogenomic signature and biomarkers for each patient. Unfortunately, the implementation of these therapies into regular clinical practice has important implications in terms of disease subtypes, long-term adverse effects and resistance profiles. In conclusion, the present study has provided evidence suggesting that immune checkpoint modulating therapy would be considered as revolutionary modality in autoimmune diseases of the future with a view to revolutionize the conventional treatment strategies based on patient-individualized and molecular-targetted approach. Dubbed COPD, chronic obstructive pulmonary disease is a progressive respiratory disease well known for its high morbidity and mortality all over the world.   Recent investigations suggest that modulation of the gut and respiratory microbiota, as well as the appearance of new pathophysiological mechanisms of COPD, are related.   This work aims to explore the relevance of microbial dysfunction in COPD and evaluate the potential of tackling the microbiome contributing to the care of COPD patients.   Here, the prospectively collected cross-sectional data from 100 COPD patients and 100 controls were analyzed by measurements of pulmonary function, immunophenotyping, and 16S rRNA sequencing.   The investigation also revealed a reduced microbial density in the patients with COPD, and a reduction in the counts of lung and gut species.  Whereas, H influenzae, M catarrhalis and P aeruginosa were higher than Lactobacillus and Bifidobacterium count. In addition, they highlighted that the investigated COPD patients had their immunity system unbalanced. Increased Th17, decreased Tregs, and increased circulating CRP, IL-6 and TNF-α.   While the two experimental treatments proved to reduce inflammation levels and enhance the lung functions, the FMT treatment also increased density and the richness of microbial communities.   The results obtained using FMT were better than what was produced by probiotics alone.   These data suggest that COPD is related to its microbiome and that such a treatment founded on the modulation of microbiota already exists.   Therefore, COPD treatment and therapy research ought to shift into targeted microbiota treatment and long-term interventional trials.